<DOC>
	<DOCNO>NCT02219828</DOCNO>
	<brief_summary>Recent finding suggest recurrent pericarditis ( RP ) may previously unrecognized autoinflammatory disease . The pivotal pathogenic role interleukin ( IL ) -1 RP show achievement complete response treatment recombinant IL-1-receptor antagonist , anakinra . Anakinra recombinant form IL-1Ra . The propose study design demonstarate efficacy anakinra RP .</brief_summary>
	<brief_title>AnakInRa Treatment Recurrent Idiopathic Pericarditis ( AIRTRIP )</brief_title>
	<detailed_description>This 8-month , multicenter ( 3 Italian center ) , randomize , double-blind , placebo-controlled , multicenter , medication-withdrawal study evaluate efficacy , tolerability , safety anakinra adult child idiopathic recurrent pericarditis ( RP ) .</detailed_description>
	<mesh_term>Pericarditis</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>1 . Patient 's write informed consent ≥ 18 year age assessment perform . Parents ' legal guardian 's write informed consent child 's assent , appropriate , required assessment perform patient &lt; 18 year age . 2 . Age &gt; 2 year &lt; 70 year screen visit ; 3 . Recurrent pericarditis define first episode acute pericarditis follow recurrence ( Ann Intern Med . 2011 ; 155:40914 ) ( least two recurrence study ) . First episode pericarditis diagnose least two follow criterion present : pericarditic typical chest pain ( sharp pleuritic , improve sit lean forward ) , pericardial friction rub , widespread ST segment elevation PR depressions previously report , new worsen pericardial effusion . Recurrence diagnose chest pain recur one follow sign present : fever , pericardial friction rub , ECG change , echocardiographic evidence new worsen pericardial effusion , elevation white blood cell count , erythrocyte sedimentation rate Creactive protein . To enrol study , elevation Creactive protein mandatory first attack follow recurrence . We differentiate recurrence incessant pericarditis , term use define patient continue activity pericarditis ( symptomfree interval &lt; 6 week ) ( SolerSoler J , SagristàSauleda J , PermanyerMiralda G. Relapsing pericarditis . Heart . 2004 ; 90:13648 ) . 4 . Specific etiology exclude , include tuberculous , neoplastic purulent etiology , postcardiac injury syndrome , rheumatic autoimmune disease . 5 . Records document number prior pericardial recurrence , time interval well prior treatment must make available medical chart . 6 . Troponin value least one previous attack record . 7 . QuantiFERON ( QFTTB G InTube ) test positive Purified Protein Derivative ( PPD ) test previously make record . 8 . Patients enrol time recurrent episode ( least second recurrence , i.e . third episode ) `` relapse '' pericarditis document follow criterion : recurrent pericardial pain ( score least 5 21 circle VAS ) AND increase CRP≥1 mg/dL ( normal value = 0 0.5 mg/dL ) , AND one follow sign : fever ( ≥ 37°C ) , pericardial friction rub , pertinent ECG change , echocardiographic evidence new worsen pericardial effusion ( see definition ) 9 . Continuous treatment CS , dose must increase three day precede enrolment 10 . Women child bear potential ( WCBP ) , define premenarche female age 8 year woman physiologically capable become pregnant , sexually active , must use effective form contraception . Medically approve contraception ( i.e . one result less 1 % per year failure rate use consistently correctly , implant , injectables , combine oral contraceptive , intrauterine device ) could include total abstinence . Reliable contraception maintain throughout study 3 month anakinra discontinuation . Women consider postmenopausal WCBP 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g . appropriate age , history vasomotor symptom ) six month spontaneous amenorrhea serum FSH level &gt; 40 mIU/mL surgical bilateral oophorectomy ( without hysterectomy ) least six week prior study entry . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment consider WCBP . Patients fulfil follow criterion eligible enrollment study : 1 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test ( &gt; 5 mIU/mL ) . 2 . History immunocompromised , include positive HIV screening ( ELISA Western blot ) test result . 3 . Positive QuantiFERON ( QFTTB G InTube ) test positive Purified Protein Derivative ( PPD ) test ( ≥ 5 mm induration ) perform first attack pericarditis . Patients positive PPD test ( ≥ 5 mm induration ) screening may enrol either negative chest Xray negative QuantiFERON test . 4 . Live vaccination within three month prior start trial , trial , three month follow last anakinra dose . 5 . History malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past 5 year , regardless whether evidence local recurrence metastases 6 . History significant medical condition , Investigator 's opinion would exclude patient participate trial include current pericarditis due know disease ( e.g . tuberculosis , neoplastic purulent cause , connective tissue disease , acute rheumatic fever , etc . ) 7 . History recurrent and/or evidence active bacterial , fungal , viral infection ( ) . 8 . History Type I hypersensitivity anakinra . 9 . History poor compliance . 10 . Use investigational drug ( biologic ) , device within five halflives drug prior study entry study .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>pericarditis</keyword>
	<keyword>recurrent pericarditis</keyword>
	<keyword>corticosteroid</keyword>
	<keyword>anakinra</keyword>
</DOC>